JP2021073453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021073453A5 JP2021073453A5 JP2021003537A JP2021003537A JP2021073453A5 JP 2021073453 A5 JP2021073453 A5 JP 2021073453A5 JP 2021003537 A JP2021003537 A JP 2021003537A JP 2021003537 A JP2021003537 A JP 2021003537A JP 2021073453 A5 JP2021073453 A5 JP 2021073453A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- proteins
- disease
- protein
- protein profile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 38
- 102000004169 proteins and genes Human genes 0.000 claims 38
- 238000000034 method Methods 0.000 claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 201000010099 disease Diseases 0.000 claims 15
- 210000003743 erythrocyte Anatomy 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 108010074328 Interferon-gamma Proteins 0.000 claims 5
- 108010065805 Interleukin-12 Proteins 0.000 claims 5
- 102000013462 Interleukin-12 Human genes 0.000 claims 5
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001007 Interleukin-8 Proteins 0.000 claims 4
- 102000004890 Interleukin-8 Human genes 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- -1 cation salt Chemical class 0.000 claims 4
- 125000002091 cationic group Chemical group 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 3
- 108090000174 Interleukin-10 Proteins 0.000 claims 3
- 102000003814 Interleukin-10 Human genes 0.000 claims 3
- 102000004388 Interleukin-4 Human genes 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- 108010002616 Interleukin-5 Proteins 0.000 claims 3
- 102000000743 Interleukin-5 Human genes 0.000 claims 3
- 210000002540 macrophage Anatomy 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 2
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108050003558 Interleukin-17 Proteins 0.000 claims 2
- 102000013691 Interleukin-17 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 claims 2
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 150000003863 ammonium salts Chemical group 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims 1
- 108010081589 Becaplermin Proteins 0.000 claims 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 claims 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 1
- 102000006573 Chemokine CXCL12 Human genes 0.000 claims 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- VJNCICVKUHKIIV-ZCFIWIBFSA-N D-dopachrome Chemical compound O=C1C(=O)C=C2N[C@@H](C(=O)O)CC2=C1 VJNCICVKUHKIIV-ZCFIWIBFSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102000000585 Interleukin-9 Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000048850 Neoplasm Genes Human genes 0.000 claims 1
- 108700019961 Neoplasm Genes Proteins 0.000 claims 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims 1
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000001099 ammonium carbonate Substances 0.000 claims 1
- 235000012501 ammonium carbonate Nutrition 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 239000005667 attractant Substances 0.000 claims 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims 1
- 229910000024 caesium carbonate Inorganic materials 0.000 claims 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000005587 carbonate group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000031902 chemoattractant activity Effects 0.000 claims 1
- 150000003841 chloride salts Chemical group 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 150000002229 francium Chemical class 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 150000002505 iron Chemical class 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003297 rubidium Chemical class 0.000 claims 1
- WPFGFHJALYCVMO-UHFFFAOYSA-L rubidium carbonate Chemical compound [Rb+].[Rb+].[O-]C([O-])=O WPFGFHJALYCVMO-UHFFFAOYSA-L 0.000 claims 1
- 229910000026 rubidium carbonate Inorganic materials 0.000 claims 1
- 229940102127 rubidium chloride Drugs 0.000 claims 1
- 238000004062 sedimentation Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034247A JP2023078210A (ja) | 2015-10-07 | 2023-03-07 | 血液の調製及びプロファイリング |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015904075A AU2015904075A0 (en) | 2015-10-07 | Blood preparation and profiling | |
| AU2015904075 | 2015-10-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537693A Division JP6824994B2 (ja) | 2015-10-07 | 2016-10-06 | 血液の調製及びプロファイリング |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034247A Division JP2023078210A (ja) | 2015-10-07 | 2023-03-07 | 血液の調製及びプロファイリング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021073453A JP2021073453A (ja) | 2021-05-13 |
| JP2021073453A5 true JP2021073453A5 (enExample) | 2021-06-24 |
Family
ID=58487130
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537693A Active JP6824994B2 (ja) | 2015-10-07 | 2016-10-06 | 血液の調製及びプロファイリング |
| JP2021003537A Pending JP2021073453A (ja) | 2015-10-07 | 2021-01-13 | 血液の調製及びプロファイリング |
| JP2023034247A Pending JP2023078210A (ja) | 2015-10-07 | 2023-03-07 | 血液の調製及びプロファイリング |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537693A Active JP6824994B2 (ja) | 2015-10-07 | 2016-10-06 | 血液の調製及びプロファイリング |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034247A Pending JP2023078210A (ja) | 2015-10-07 | 2023-03-07 | 血液の調製及びプロファイリング |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11243218B2 (enExample) |
| EP (2) | EP4009047A1 (enExample) |
| JP (3) | JP6824994B2 (enExample) |
| KR (1) | KR102632490B1 (enExample) |
| CN (2) | CN108700565B (enExample) |
| AU (1) | AU2016334875B2 (enExample) |
| CA (1) | CA3001154C (enExample) |
| HK (1) | HK1258470A1 (enExample) |
| SG (1) | SG11201802754XA (enExample) |
| WO (1) | WO2017059477A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3009369A1 (en) | 2015-12-22 | 2017-06-29 | Sangui Bio Pty. Ltd | Therapeutic methods using erythrocytes |
| WO2018112500A1 (en) * | 2016-12-20 | 2018-06-28 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
| CN108715833B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种负载血小板裂解液的微球制备方法 |
| US20240352423A1 (en) * | 2021-03-10 | 2024-10-24 | Terasaki Institute For Biomedical Innovation | Methods and systems of producing products such as animal derived products |
| CN114081899A (zh) * | 2021-11-02 | 2022-02-25 | 四川大学华西医院 | 一种富白细胞富血小板血浆的制备方法 |
| US20250085283A1 (en) | 2022-03-23 | 2025-03-13 | Teijin Limited | Method for quantifying nicotinamide adenine dinucleotide (nad+) or nicotinamide mononucleotide (nmn), and kit and filter paper for performing the method |
| WO2024010763A1 (en) * | 2022-07-07 | 2024-01-11 | Russell Biotech, Inc. | Preparation of platelet free mononuclear cells |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931276A (en) | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| WO1992005801A1 (en) | 1990-10-04 | 1992-04-16 | University Of Virginia Alumni Patents Foundation | Primate erythrocyte bound monoclonal antibody heteropolymers |
| ES2167391T3 (es) * | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
| US5763280A (en) * | 1997-01-21 | 1998-06-09 | Coulter International Corp. | Cyanide-free lytic reagent composition and method for hemoglobin and cell analysis |
| FR2778851B1 (fr) | 1998-05-19 | 2002-07-26 | Aetsrn | Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes |
| US8431117B2 (en) | 1999-08-30 | 2013-04-30 | David S Terman | Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects |
| AU2001272670A1 (en) | 2000-07-24 | 2002-02-05 | Gendel Limited | Polypeptide delivery II-2 |
| PT1495328E (pt) | 2002-04-16 | 2014-09-09 | Vlaams Interuniv Inst Biotech | Um marcador para medir cirrose hepática |
| US7501286B2 (en) | 2002-08-14 | 2009-03-10 | President And Fellows Of Harvard College | Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry |
| US7276382B2 (en) * | 2003-10-02 | 2007-10-02 | Noboru Horiguchi | Blood testing method |
| GB0325483D0 (en) | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
| US20080095749A1 (en) | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| US7378054B2 (en) | 2004-04-16 | 2008-05-27 | Savvipharm Inc | Specimen collecting, processing and analytical assembly |
| US7803523B2 (en) * | 2004-08-27 | 2010-09-28 | University Health Network | Whole blood preparation for cytometric analysis of cell signaling pathways |
| US20060166223A1 (en) | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
| WO2006123253A2 (en) | 2005-03-29 | 2006-11-23 | Inverness Medical Switzerland Gmbh | Device and method of monitoring a patient |
| US20100184049A1 (en) | 2007-04-27 | 2010-07-22 | Steve Goodison | Glycoprotein Profiling of Bladder Cancer |
| FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
| US8530182B2 (en) | 2007-12-05 | 2013-09-10 | Centers For Disease Control And Prevention | Viral protein quantification process and vaccine quality control therewith |
| US20110245092A1 (en) | 2008-03-04 | 2011-10-06 | John Bilello | Diagnosing and monitoring depression disorders based on multiple serum biomarker panels |
| KR20210003301A (ko) | 2008-05-06 | 2021-01-11 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법 |
| EP2442641A4 (en) | 2009-06-16 | 2016-03-09 | Univ Columbia | METHOD FOR REDUCING SIDE EFFECTS OF THE TRANSFUSION OF AGED RED BLOOD CELLS |
| JP6162359B2 (ja) * | 2009-06-30 | 2017-07-12 | 株式会社カネカ | 血液成分の分離システム、分離材 |
| EP2464966A1 (en) | 2009-08-13 | 2012-06-20 | Basf Se | Means and methods for diagnosingthyroid disorders |
| US20130202625A1 (en) | 2010-01-21 | 2013-08-08 | The Regents Of The University Of Californa | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
| SG183195A1 (en) | 2010-02-08 | 2012-09-27 | Piramal Imaging Sa | F18-tyrosine derivatives for imaging bone metastases |
| WO2011127056A2 (en) | 2010-04-05 | 2011-10-13 | The Uab Research Foundation | Biomarkers for assessing exposure to ionizing radiation and absorbed dose |
| SG195180A1 (en) | 2011-05-31 | 2013-12-30 | Singapore Health Serv Pte Ltd | Method for detecting disease biomarkers |
| GB201116767D0 (en) | 2011-09-28 | 2011-11-09 | St George S Hospital Medical School | Treatment for mitrochondrial neurogastrointestinal encephalomyopathy |
| CN104394884A (zh) | 2012-03-21 | 2015-03-04 | 爱瑞泰克药物公司 | 用于治疗急性髓细胞白血病(aml)的药剂 |
| HU230341B1 (hu) | 2012-04-20 | 2016-02-29 | Advancell Diagnosztika Kft. | A vörösvérsejt-membrán kvantitatív biomarkerei |
| EP2872154B1 (en) | 2012-07-11 | 2017-05-31 | Sangamo BioSciences, Inc. | Methods and compositions for delivery of biologics |
| EP2994117B1 (en) | 2013-05-10 | 2023-06-07 | EryDel S.p.A. | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes |
| JP6383920B2 (ja) * | 2013-09-11 | 2018-09-05 | 有限会社ピコデバイス | パーキンソン病の判定基準とする方法 |
| CN106255884B (zh) * | 2013-10-04 | 2019-01-11 | 赛尔爱迪尔私人有限公司 | 用于细胞治疗的生物标志物 |
| KR101845588B1 (ko) | 2014-04-07 | 2018-04-05 | 한양대학교 산학협력단 | 적혈구계 세포의 인 비트로 확장 |
| BR122021024421B1 (pt) | 2015-05-18 | 2022-05-03 | Hemanext Inc | Usos de um produto de sangue total armazenado reduzido de oxigênio com plaquetas |
| CA3009369A1 (en) | 2015-12-22 | 2017-06-29 | Sangui Bio Pty. Ltd | Therapeutic methods using erythrocytes |
| WO2018112500A1 (en) | 2016-12-20 | 2018-06-28 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
-
2016
- 2016-10-06 CN CN201680071446.0A patent/CN108700565B/zh active Active
- 2016-10-06 EP EP21207712.7A patent/EP4009047A1/en active Pending
- 2016-10-06 AU AU2016334875A patent/AU2016334875B2/en active Active
- 2016-10-06 WO PCT/AU2016/000341 patent/WO2017059477A1/en not_active Ceased
- 2016-10-06 HK HK19100786.7A patent/HK1258470A1/zh unknown
- 2016-10-06 US US15/765,963 patent/US11243218B2/en active Active
- 2016-10-06 JP JP2018537693A patent/JP6824994B2/ja active Active
- 2016-10-06 CA CA3001154A patent/CA3001154C/en active Active
- 2016-10-06 EP EP16852887.5A patent/EP3359962B1/en active Active
- 2016-10-06 SG SG11201802754XA patent/SG11201802754XA/en unknown
- 2016-10-06 KR KR1020187012951A patent/KR102632490B1/ko active Active
- 2016-10-06 CN CN202111208795.1A patent/CN114019171A/zh active Pending
-
2021
- 2021-01-13 JP JP2021003537A patent/JP2021073453A/ja active Pending
-
2023
- 2023-03-07 JP JP2023034247A patent/JP2023078210A/ja active Pending
- 2023-11-13 US US17/845,451 patent/US20240060997A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Cytokine signature associated with disease severity in COVID-19 | |
| Boucly et al. | Cytokines as prognostic biomarkers in pulmonary arterial hypertension | |
| Morimoto et al. | Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis | |
| Maruoka et al. | IP-10/CXCL10 and MIG/CXCL9 as novel markers for the diagnosis of lymphoma-associated hemophagocytic syndrome | |
| Zhang et al. | Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis | |
| JP2018530766A5 (enExample) | ||
| Khoury et al. | Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder | |
| Hayashi et al. | Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib | |
| US20210255183A1 (en) | Method for predicting therapeutic effect of biological preparation on rheumatoid arthritis | |
| Thuma et al. | Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia | |
| Doerflinger et al. | Procalcitonin and interleukin-10 may assist in early prediction of bacteraemia in children with cancer and febrile neutropenia | |
| Xu et al. | Simple evaluation of clinical situation and subtypes of pediatric hemophagocytic lymphohistiocytosis by cytokine patterns | |
| AU2016334875B2 (en) | Blood preparation and profiling | |
| US12560614B2 (en) | Method for diagnosing and treating fibromyalgia | |
| Kleiner et al. | Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17 | |
| Gibellini et al. | Plasma cytokine atlas reveals the importance of TH2 polarization and interferons in predicting COVID-19 severity and survival | |
| Hocum Stone et al. | Serum cytokine profiles in healthy nonhuman primates are blunted by sedation and demonstrate sexual dimorphism as detected by a validated multiplex immunoassay | |
| Cheng et al. | Simultaneous measurement of twenty-nine circulating cytokines and growth factors in female patients with overt autoimmune thyroid diseases | |
| Arsentieva et al. | Predictive value of specific cytokines for lethal COVID-19 outcome | |
| Harasawa et al. | Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma | |
| Imaizumi et al. | Involvement of retinoic acid-inducible gene-I in the IFN-γ/STAT1 signalling pathway in BEAS-2B cells | |
| Lereim et al. | Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival | |
| Di et al. | Role of chemotaxis of Vδ2 T cells to the synovium in the pathogenesis of acute gouty arthritis | |
| MacLaughlin et al. | 100% oxygen mobilizes stem cells and up-regulates MIF and APRIL in humans: a new point on the hormetic dose curve | |
| Stelmasiak et al. | IL-6 and sIL-6R concentration in the cerebrospinal fluid and serum of MS patients. |